OR WAIT null SECS
September 17, 2021
GeneQuine Biotherapeutics has chosen Exothera to advance the development of its osteoarthritis gene therapy product candidate, GQ-303.
September 16, 2021
The joint venture with OSTHUS will expand PharmaLex’s IT consulting and system integration expertise.
CPC’s MicroCNX Series Connectors provide an alternative to tube welding at small tubing sizes.
AzurRx’s acquisition of First Wave Bio grants them access to their proprietary niclosamide formulations.
FDA and EMA will provide scientific advice to applicants concerning complex generic and hybrid products.
September 14, 2021
Repligen and Navigo’s novel ligand could be the first to address antibody aggregation in low pH elution buffers.
AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.
HUTCHMED’s amdizalisib (HMPL-689) received breakthrough therapy designation for the treatment of a subtype of non-Hodgkin’s lymphoma.
Both Marion Gruber and Phillip Krause, FDA officials, co-authored a document disputing the need for COVID-19 boosters for most people.
September 13, 2021
The memorandum of understanding between ABITEC and Luca AICell will work to advance ultra-high purity lipidic chemistries.